Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsRaw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pulmonx (LUNG) Preferred Stock Liabilities (2019 - 2020)

Pulmonx (LUNG) has disclosed Preferred Stock Liabilities for 2 consecutive years, with $207.6 million as the latest value for Q3 2020.

  • Quarterly Preferred Stock Liabilities rose 1.1% to $207.6 million in Q3 2020 from the year-ago period, while the trailing twelve-month figure was $207.6 million through Sep 2020, up 1.1% year-over-year, with the annual reading at $205.3 million for FY2019, 46.11% up from the prior year.
  • Preferred Stock Liabilities for Q3 2020 was $207.6 million at Pulmonx, roughly flat from $207.6 million in the prior quarter.
  • The five-year high for Preferred Stock Liabilities was $207.6 million in Q1 2020, with the low at $205.3 million in Q3 2019.